Immunome shares surged after the company reported positive topline data from its Phase 3 RINGSIDE trial. The study met its primary endpoint, showing improved progression-free survival, while Varegacestat delivered a 56% response rate versus 9% for placebo. Immunome plans an FDA filing in Q2 2026.